Cognition

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Retrieved on: 
torsdag, maj 9, 2024
Disorder, Common, Risk, GC, Overweight, Trial of the century, Adrenocorticotropic hormone, Hyperlipidemia, Associate, Deficit spending, Hydrocortisone, Neurocrine Biosciences, White matter, Food, Oklahoma State University–Stillwater, Cognition, Psychology, Testosterone, Male, Literature, Brain, DSM-IV codes, A4, SAN, GCS, CAH, Acne, Safety, Glucocorticoid, Research, Depression, Congenital adrenal hyperplasia, Osteopenia, Anxiety, Division, Hirsutism, Androstenedione, Psychiatry, Psychosis, Hypertension, Metabolism, Poster, Pharmaceutical industry

The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.

Key Points: 
  • The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
  • These new data were presented at oral presentations and poster sessions at the American Association of Clinical Endocrinology 2024 Annual Meeting in New Orleans.
  • Despite supraphysiologic GC dosing, levels of adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione (A4) were elevated at baseline, with levels of testosterone (females) and A4/testosterone (males) also elevated.
  • The data from both studies supported two New Drug Applications submitted to the U.S. Food and Drug Administration in April 2024.

Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Retrieved on: 
torsdag, maj 9, 2024
Safety, Pharmacokinetics, Cognition, Trial of the century, Neurocrine Biosciences, Patient, Pharmaceutical industry

NBI-1117567 is an investigational, oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera that may have the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions.

Key Points: 
  • NBI-1117567 is an investigational, oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera that may have the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions.
  • The clinical development milestone achieved with this compound as announced does not trigger a milestone payment from Neurocrine to Nxera under the terms of the 2021 agreement between the companies.
  • Milestone payments, under the agreement, are payable upon the achievement of multiple, defined development events for each program.
  • Nxera will announce the receipt of any milestone payments in accordance with TSE reporting requirements.

Clinical Study Highlights Improvements to Gut Microbiome and Autism Spectrum Disorder Symptoms with Use of Custom Probiotics

Retrieved on: 
tisdag, maj 7, 2024
PGIA, Social Responsiveness Scale, ASU, Language, M-Systems, Arizona State University, Spectrum, Comprehension, Metagenomics, Health, Cognition, Thought, Trial of the century, Research, Speech, MTT, Diet, Probiotic, Caregiver, Genomics, Clinical trial, Quality of life, SAN, Dietary supplement

“Our research uncovered critical insight into the connection between precision nutrition – in the form of precision probiotics – and both gut health and autism spectrum disorder.

Key Points: 
  • “Our research uncovered critical insight into the connection between precision nutrition – in the form of precision probiotics – and both gut health and autism spectrum disorder.
  • The clinical research was conducted with the participation of 296 children and adults diagnosed with autism spectrum disorder and 123 age-matched neurotypical controls.
  • Behavioral and Autism Symptoms: Follow-up surveys revealed moderate improvement in thinking abilities, sensory experiences and overall autism-related symptoms among participants.
  • The next step is a randomized, double-blind and placebo-controlled study, which is needed to confirm the clinical study findings.

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
tisdag, maj 7, 2024
Lewy body, SHIMMER, DLB, Research, Cognition, Public expenditure, SHINE, Therapy, NIA, Pharmaceutical industry

PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2025.
  • Research and development expenses were $10.6 million for the quarter ended March 31, 2024, compared to $5.4 million for the comparable period in 2023.
  • General and administrative expenses were $3.5 million for the quarter ended March 31, 2024, compared to $3.5 million for the comparable period in 2023.

Mikra Announces Joint Product with Jose Bautista

Retrieved on: 
måndag, maj 6, 2024
Caffeine, Brain, FOCUS, Animal, Cognition, Research, Nutrient, Human, Phenylalanine, Science, MLB, Pleasure, Tyrosine, Memory, Crash, Neuron, Olympic, Mount Sinai Hospital, Regeneration, Sleep, Systematic review, Dietary supplement

Mikra’s new product FOCUS combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver superior clarity of cognition and improved memory without any caffeine or stimulants.

Key Points: 
  • Mikra’s new product FOCUS combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver superior clarity of cognition and improved memory without any caffeine or stimulants.
  • We deeply appreciate his contributions as an elite athlete with unique insights into achieving peak human performance.
  • “It’s been a blast working with Team Mikra on developing FOCUS,” said Jose Bautista.
  • “It is an absolute pleasure to be collaborating with Jose Bautista to develop FOCUS, leveraging his experience both as an accomplished entrepreneur and as an elite athlete with extensive firsthand knowledge of cutting-edge nutraceutical supplementation.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
torsdag, maj 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Retrieved on: 
måndag, maj 6, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, The Association, License, ADOA, Dravet syndrome, Cognition, MECP2, SYNGAP1, RNA, Rett syndrome, Acadia Pharmaceuticals, Cell, Conference, Seizure, CNS, Therapy, OLE, Patient, Gene, Society, Medicine, Collaboration, Central nervous system, Behavior, ARVO, Pharmaceutical industry

“In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.

Key Points: 
  • “In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • These data showed substantial and durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior that support the potential for disease modification.
  • The Company expanded and strengthened its management team with the appointments of Jason Hoitt as Chief Commercial Officer and Thomas (Tommy) Leggett as Chief Financial Officer.
  • General and administrative expenses for the three months ended March 31, 2024 were $10.2 million, compared to $10.2 million for the same period in 2023.

Cisco Unlocks AI-Powered Intelligence for Self-Hosted Observability

Retrieved on: 
onsdag, maj 8, 2024
Public sector, Organization, Amazon Web Services, Investment, Attack, Flex, RASP, Software, Cognition, Java, AMI, Workload, Software as a service, CSCO, VHD, Secure, Intelligence, AppDynamics, Senior, Microsoft, Root cause analysis, Anomaly, Azure, IDC, Microsoft Azure, Government, Application security, SAN, AWS, SAP, Health, VHD (file format), Risk management

SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Cisco (NASDAQ: CSCO) today announced a new virtual appliance for its AppDynamics On-Premises application observability offering, enabling customers to use a self-hosted observability solution built on AI-powered intelligence for anomaly detection and root cause analysis, application security, and SAP monitoring. The latest innovations allow IT operations teams to detect application performance anomalies faster and with greater accuracy, protect against security vulnerabilities and attacks, and maintain the performance of SAP applications and business processes, all while retaining full control of their observability deployment. Cisco also announced AppDynamics Flex, a new licensing model that provides optionality for customers to choose between self-hosted and Software-as-a-Service (SaaS) observability offerings and support them through the transition from self-hosted to SaaS when the time is right for their business.  

Key Points: 
  • SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Cisco (NASDAQ: CSCO) today announced a new virtual appliance for its AppDynamics On-Premises application observability offering, enabling customers to use a self-hosted observability solution built on AI-powered intelligence for anomaly detection and root cause analysis, application security, and SAP monitoring.
  • While there has been a significant increase in demand for SaaS observability solutions in recent years, for many organizations, self-hosted observability solutions remain in high demand.
  • Self-hosted observability - also referred to as customer-managed observability - includes on-premises deployments or cloud-based deployments where the customer retains control of all the data and associated operations.
  • "As a partner for Cisco AppDynamics and Full-Stack Observability, SG Solutions is committed to helping our joint customers with observability solutions for their applications wherever their business regulation requires," said Jindřich Kasal, CEO, SG Solutions.

Dr. Ahmed Z. Obeidat Named Finalist for the 2024 "CMSC Neuroinnovator of the Year"

Retrieved on: 
måndag, maj 6, 2024
Dementia, Prevalence, Dermatology, Cognition, Thought, Research, Light, Background, Patient, Fatigue, Psoriasis, Biomarker, Light therapy, Walking, CMSC, Medical college, Pharmaceutical industry

"This trial targets the biggest unmet need in MS, which is fatigue and the cognitive difficulties associated with it. The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat. "I think the inclusive target patient population within the Silent Symptoms trial will change our thinking about who should be enrolled in clinical trials. Most trials have been very selective -- excluding people who are not walking, or are over age 60, and so on. The Silent Symptoms trial will go all in, taking any MS patient with fatigue, which is the vast majority of our patients, and offering them phototherapy lights that they can take home."

Key Points: 
  • The recognition highlights the groundbreaking work and innovative approach sponsored by Cytokind, Inc. in addressing unmet needs in MS treatment.
  • The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat.
  • The 2024 CMSC Neuroinnovation Competition aims to recognize and celebrate original and innovative work in the field of MS research.
  • The finalists will present their ideas at the annual CMSC conference in Nashville, Tennessee, from May 29 to June 1.

BrainCheck Highlights Comprehensive Digital Cognitive Assessment Platform at MDVIP National Meeting

Retrieved on: 
torsdag, maj 2, 2024
FDA, Dementia, Cognition, Documentation, Molina Healthcare, Patient, Physician, Health, NewYork-Presbyterian Queens, MDVIP, Deficit spending, Montreal Cognitive Assessment, Nursing

AUSTIN, Texas, May 2, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will highlight its comprehensive platform in booth #8 at the upcoming MDVIP National Meeting, from May 3-5, in National Harbor, MD.

Key Points: 
  • Company's next-generation tools for cognitive screening, assessment, and care planning set to empower MDVIP-affiliated physicians to enhance cognitive healthcare
    AUSTIN, Texas, May 2, 2024 /PRNewswire/ -- BrainCheck, Inc. , a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will highlight its comprehensive platform in booth #8 at the upcoming MDVIP National Meeting, from May 3-5, in National Harbor, MD.
  • "BrainCheck's technology offers a simple solution to these challenges by providing clinicians with a comprehensive set of user-friendly digital tools for cognitive screening, assessment, and care planning.
  • Trusted by hundreds of the country's most prestigious providers and specialists, BrainCheck's clinically proven platform offers a comprehensive solution streamlining screening, assessment, care planning, and monitoring.
  • BrainCheck's platform also includes Plan™, which streamlines the development and documentation of comprehensive care plans for patients with cognitive decline, post-diagnosis.